pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX
TG THERAPEUTICS
TG THERAPEUTICS, INC.
TG THERAPEUTICS clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
- Founded
- 2011
- Employees
- 521
- Programs
- 39
- Drugs
- 23
- Patents
- 7
TG THERAPEUTICS projects
9 ClinicalTrials.gov programs sponsored by TG THERAPEUTICS.
TG THERAPEUTICS has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Obinutuzumab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
TG1101-RMS-PED304
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
1 trial -
TG1101-RMS401
TG THERAPEUTICS, INC.
Relapsing multiple sclerosis
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
5 trials -
Ublituximab
TG THERAPEUTICS, INC.
Diffuse Large B-Cell Lymphoma
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
3 trials -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis (RMS)
3 trials -
Ublituximab, ublituximab
TG THERAPEUTICS, INC.
Relapsing forms of Multiple Sclerosis
1 trial -
ublituximab
TG THERAPEUTICS, INC.
relapsing multiple sclerosis
1 trial
Frequently asked questions
How many clinical projects does TG THERAPEUTICS have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.